Literature DB >> 29844826

Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients.

Wei Liu1, Yanmiao Huo1, Jianyu Yang1, Xueliang Fu1, Minwei Yang1, Lingye Tao1, Dejun Liu1, Junfeng Zhang1, Rong Hua1, Yongwei Sun1.   

Abstract

The present study aimed to investigate the expression level of ubiquitin specific peptidase 9X (USP9X) and its clinical significance in Chinese patients with pancreatic ductal adenocarcinoma (PDAC). The mRNA expression levels of USP9X in 30 paired PDAC tissue samples were examined by reverse transcription-quantitative polymerase chain reaction. The protein expression of USP9X was analyzed by immunohistochemistry (IHC) in a tissue microarray containing 205 PDAC specimens. All analyses were performed by SPSS 20.0 and GraphPad Prism 5.0 software. The USP9X mRNA level was significantly decreased in 18/30 (60.0%) PDAC tissue samples compared with matched surrounding non-tumor tissue samples. The results of IHC revealed that decreased expression of USP9X was inversely associated with liver metastasis (P=0.032). Kaplan-Meier survival curves indicated that patients with high expression of USP9X presented a longer clinical overall survival time (P<0.001). Univariate and multivariate COX regression analysis revealed that USP9X protein expression level was a significant, and independent prognostic factor for the overall survival rate of patients with PDAC. The results of the present study indicate that USP9X may serve as a candidate tumor suppressor and prognostic biomarker in PDAC.

Entities:  

Keywords:  USP9X; expression; pancreatic ductal adenocarcinoma; prognosis; tumor suppressor

Year:  2018        PMID: 29844826      PMCID: PMC5958808          DOI: 10.3892/ol.2018.8452

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  21 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The Drosophila developmental gene fat facets has a human homologue in Xp11.4 which escapes X-inactivation and has related sequences on Yq11.2.

Authors:  M H Jones; R A Furlong; H Burkin; I J Chalmers; G M Brown; O Khwaja; N A Affara
Journal:  Hum Mol Genet       Date:  1996-11       Impact factor: 6.150

3.  Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma.

Authors:  Jesse L Cox; Phillip J Wilder; Erin L Wuebben; Michel M Ouellette; Michael A Hollingsworth; Angie Rizzino
Journal:  Cancer Biol Ther       Date:  2014-05-19       Impact factor: 4.742

4.  Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer.

Authors:  Hua Jiang; Qingqing Li; Chengzhi He; Fengru Li; Haihui Sheng; Xiaoying Shen; Xiaoyan Zhang; Shizhang Zhu; Hui Chen; Ximei Chen; Changqing Yang; Hengjun Gao
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

5.  Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines.

Authors:  Ulrika Rolén; Vera Kobzeva; Natalja Gasparjan; Huib Ovaa; Gösta Winberg; Fjodor Kisseljov; Maria G Masucci
Journal:  Mol Carcinog       Date:  2006-04       Impact factor: 4.784

6.  Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.

Authors:  Shan Wang; Rahul K Kollipara; Nishi Srivastava; Rui Li; Preethi Ravindranathan; Elizabeth Hernandez; Eva Freeman; Caroline G Humphries; Payal Kapur; Yair Lotan; Ladan Fazli; Martin E Gleave; Stephen R Plymate; Ganesh V Raj; Jer-Tsong Hsieh; Ralf Kittler
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

7.  The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

Authors:  Pedro A Pérez-Mancera; Alistair G Rust; Louise van der Weyden; Glen Kristiansen; Allen Li; Aaron L Sarver; Kevin A T Silverstein; Robert Grützmann; Daniela Aust; Petra Rümmele; Thomas Knösel; Colin Herd; Derek L Stemple; Ross Kettleborough; Jacqueline A Brosnan; Ang Li; Richard Morgan; Spencer Knight; Jun Yu; Shane Stegeman; Lara S Collier; Jelle J ten Hoeve; Jeroen de Ridder; Alison P Klein; Michael Goggins; Ralph H Hruban; David K Chang; Andrew V Biankin; Sean M Grimmond; Lodewyk F A Wessels; Stephen A Wood; Christine A Iacobuzio-Donahue; Christian Pilarsky; David A Largaespada; David J Adams; David A Tuveson
Journal:  Nature       Date:  2012-04-29       Impact factor: 49.962

8.  High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma.

Authors:  Yanmiao Huo; Minwei Yang; Wei Liu; Jianyu Yang; Xueliang Fu; Dejun Liu; Jiao Li; Junfeng Zhang; Rong Hua; Yongwei Sun
Journal:  J Exp Clin Cancer Res       Date:  2015-08-22

9.  USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Jing Peng; Qian Hu; Weiping Liu; Xiaoli He; Ling Cui; Xinlian Chen; Mei Yang; Hongqian Liu; Wei Wei; Shanling Liu; He Wang
Journal:  Diagn Pathol       Date:  2013-10-23       Impact factor: 2.644

10.  The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.

Authors:  Chander Peddaboina; Daniel Jupiter; Steven Fletcher; Jeremy L Yap; Arun Rai; Richard P Tobin; Weihua Jiang; Philip Rascoe; M Karen Newell Rogers; W Roy Smythe; Xiaobo Cao
Journal:  BMC Cancer       Date:  2012-11-21       Impact factor: 4.430

View more
  1 in total

Review 1.  Deubiquitinases in Cancers: Aspects of Proliferation, Metastasis, and Apoptosis.

Authors:  Jiaqi Liu; Chi Tim Leung; Luyun Liang; Yuqin Wang; Jian Chen; Keng Po Lai; William Ka Fai Tse
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.